The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers ...

Ozempic and Wegovy have become popular options for people looking to lose weight, but there are some risks and side effects ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...